Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.45 |
| ▸ | FPR2 | P25090 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953290 | 1.00 | SCN9A (0.45) | SCN9AFPR2MEN1KMT2ALMNA | |
| SCHEMBL12127970 | 0.77 | TRPM8 (0.39) | SCN9AMEN1KMT2ARECQLMAPT | |
| SCHEMBL14744428 | 0.76 | LMNA (0.53) | SCN9AFPR2LMNA | |
| SCHEMBL14743282 | 0.76 | FPR2 (0.55) | SCN9AFPR2LMNA | |
| SCHEMBL14743286 | 0.76 | LMNA (0.53) | SCN9AFPR2LMNA | |
| SCHEMBL14743280 | 0.76 | FPR2 (0.55) | SCN9AFPR2LMNA | |
| SCHEMBL11292581 | 0.74 | MEN1 (0.45) | SCN9AFPR2MEN1KMT2ALMNA | |
| SCHEMBL9953216 | 0.74 | SCN9A (0.84) | SCN9AFPR2 | |
| SCHEMBL9953218 | 0.74 | SCN9A (0.84) | SCN9AFPR2 | |
| SCHEMBL14743671 | 0.73 | SCN9A (0.45) | SCN9AFPR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656959-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2655330-B1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2655330-B1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20140005212-A1 | Substituted Pyridines as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2655330-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005212-A1 | Substituted Pyridines as Sodium Channel Blockers | SCN1B, CACNA1A, SCN1A | SCN9A 97/4885FPR2 1488/4885MEN1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.